FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

LALPATHLAB

1,720
+53.35 (3.2%)
Updated 03:28 07/07 IST

LALPATHLAB Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for LALPATHLAB
Disclaimer
0% Bullish
0% Bearish

LALPATHLAB Buy or Sell - Brokerage Reports

No. of reports in last year
4
No. of analysts
2
Average Consensus Forecast
1274.25
Consensus Potential
-39.37%
See LALPATHLAB Share Price Targets >>

LALPATHLAB Ratings

Long term LALPATHLAB rating by FrontPage users
3.5/5 (2 Ratings)
Find answers to all your questions on live LALPATHLAB message board: Is LALPATHLAB buy or sell? Should I buy LALPATHLAB shares? Why are LALPATHLAB shares falling? Should I invest in LALPATHLAB stock?

  1. Home
  2. LALPATHLAB Forum

LALPATHLAB Share Price Discussion

N
Reputation: 3,913 • Today 10:08 AM
Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs
The company, in its Annual Report for 2019-20, stated that instances and situations like the COVID-19 outbreak further boost the importance of diagnostics as an integral part of healthcare system.
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Today 9:36 AM
Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs
The company said it served 1.94 crore patients and processed 4.77 crore samples
The Economic Times
Like
Reply
N
Reputation: 3,913 • Jul 5 6:33 AM
'These tech companies will continue to generate greater returns in future'
I think most pharma stocks are overvalued now, and the rally will stablise now, says Sumit Bilgaiyan, the founder of Equity99.
Moneycontrol
Like
Reply
A
Reputation: 3,741 • Jun 19 4:59 AM

Type
Buy
Instrument
LALPATHLAB
Entry Price
₹1,535.05
Price@Trade
₹1,535.05
Target Price
₹1,680
Stop Price
₹1,450
Valid Till
Jun 18, 2021 3:20 AM
Margin
₹767,525 approx for 500 Qty
Status
Target Achieved
Exit Price
₹1,680
Net P&L
+₹72,475 (+9.44%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 2:53 AM

Update
Target Achieved
Exit Price
₹1,680

Type
Buy
Instrument
LALPATHLAB
Entry Price
₹1,535
Price@Trade
₹1,534.05
Target Price
₹1,680
Stop Price
₹1,450
Valid Till
Jun 18, 2021 3:20 AM
Margin
₹153,500 approx for 100 Qty
Status
Target Achieved
Exit Price
₹1,680
Net P&L
+₹14,500 (+9.45%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 19 3:53 AM

Update
Trade Entered
Entry Price
₹1,535
TrackerBot @trackerbot
Yesterday 2:53 AM

Update
Target Achieved
Exit Price
₹1,680
D
Reputation: 17,391 • May 19 5:00 AM

Prabhudas Lilladher target on LALPATHLAB
Date: 19-May-20 Broker: Prabhudas Lilladher Price @ Call: 1583.35 Target: 895 Recommendation: SELL
Like
Reply
N
Reputation: 3,913 • May 19 4:43 AM
Sell Dr. Lal PathLabs; target of Rs 895: Prabhudas Lilladher
Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 895 in its research report dated May 19, 2020.
Moneycontrol
Like
Reply

*Result Highlight*
Glaxosmithkline Pharmaceuticals Ltd. Q4 Cons: Net profit down -6% at Rs. 138.07 cr. Vs Rs. 146.81 cr. (YoY) and Revenue up 3.3% at Rs. 775.8 cr. Vs Rs. 750.81 cr. (YoY)
Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 eac...
Read more...
3
Reply
N
Reputation: 3,913 • May 9 1:43 AM
Opportunity is pharma is huge, advise investors to invest: Motilal Oswal
As lockdown mode could continue and the government's ability to come out with an aggressive bailout package is limited, it's difficult to make out a case for big upside in the short run.
Moneycontrol
Like
Reply
T
Reputation: -5,817 • May 8 4:38 AM

*DR LAL PATHLAB Rs 16.15 CRS NSE BLOCK FOR ~ 100350 SHARES, AT RS 1609.50*
Like
Reply
N
Reputation: 3,913 • May 7 5:33 AM
Drop airlines! Here are top 10 stocks based on Warren Buffett's investment methodology
Warren Buffett once again showed investors as to how one can cut losses and preserve cash. The investing phenomenon is dynamic in nature and usually changes over a period of time based on the prevailing trend.
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Apr 30 8:18 AM
Brokerages initiate buy on 11 stocks after COVID-led fall, expect 10-49% upside
Majority of experts started advising clients to accumulate quality stocks in a gradual manner with a long term view
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Apr 28 1:03 AM
Hot Stocks | Granules India, Dr Lal Path Lab, Navin Flourine are short-term buys
Positional Support for Nifty is seen at 8,900, and unless that is breached, the short-term trend of the market would be considered bullish only.
Moneycontrol
Like
Reply
T
Reputation: -5,817 • Apr 27 8:28 AM

*DR LAL PATHLAB Rs 16.05 CRS NSE BLOCK FOR ~ 103775 SHARES, AT RS 1546.25*
Like
Reply
N
Reputation: 3,913 • Apr 13 7:43 AM
Analysts suggest these 15 quality mid-caps for 1-year investment horizon
Due to the COVID-19 pandemic, most large and mid-cap stocks have corrected significantly. They are expected to remain volatile unless the issue of coronavirus comes under control.
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Apr 1 7:53 AM
Coronavirus pain may linger; 10 stocks you can consider for your portfolio
Brokerages and analysts are of the view that the pain caused by COVID-19 may linger and the market is factoring in the hit on earnings and economic fallout from coronavirus outbreak.
Moneycontrol
Like
Reply

*SHORT TERM*
BUY DR LAL PATH LABS
BUY NEAR 1525-30
STOPLOSS
1400
TGT 1650 /1750/1900
Like
Reply
N
Reputation: 3,913 • Mar 18 4:58 AM
Thyrocare Tech, Dr Lal PathLabs rise 9% as govt allow private lab to do coronavirus testing
The total number of coronavirus cases in India rose to 147, with 10 fresh cases reported from various parts of the country.
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Mar 18 1:23 AM
Coronavirus pandemic: Private labs can scale up Covid-19 testing by 10x, but safety concerns remain
Despite best efforts, the government labs are only able to do 6,000 tests a day with a waiting period of two days.
Moneycontrol
Like
Reply
I
Reputation: 2,343 • Mar 4 6:51 AM
LALPATHLAB

Type
Buy
Instrument
LALPATHLAB
Entry Price
₹1,708
Price@Trade
₹1,709.85
Target Price
₹1,750
Stop Price
₹1,680
Valid Till
Apr 3, 2020 3:20 AM
Margin
₹1,708 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹1,680
Net P&L
-₹28.01 (-1.64%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Mar 4 6:52 AM

Update
Trade Entered
Entry Price
₹1,708
TrackerBot @trackerbot
Mar 4 7:14 AM

Update
Stoploss Hit
Exit Price
₹1,680
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • LALPATHLAB - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization8,783.99
    Enterprise Value8,305.89
    Price to Earnings43.63
    Price to Book Value9.44
    Return on Capital Employed0.33
    Return on Equity0.21
    Face Value10
    Dividend Yield0.01
  • LALPATHLAB - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    19-May-20Prabhudas LilladherSell895
    4-Feb-20Prabhudas LilladherHold1,797
    23-Aug-19Karvy Stock BrokingHold1,285
    14-Aug-19Prabhudas LilladherAccumulate1,120
    20-May-19Prabhudas LilladherAccumulate1,120
    LALPATHLAB Brokerage Price Target
  • LALPATHLAB Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 71666.51748.81655.051717.1
    Jul 61630168016301666.65
    Jul 3157916261573.11617.75
    Jul 2158815881564.951570.9
    Jul 1157115801543.11577.55
  • LALPATHLAB Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,592.12
    30 Day Moving Average₹1,581.5
    50 Day Moving Average₹1,574.63
    100 Day Moving Average₹1,559.67
    200 Day Moving Average₹1,536.05
  • LALPATHLAB - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,024881.870.16
    Operating Profit256229.090.12
    Profit Before Tax255222.90.14
    Net Income167147.210.13
  • LALPATHLAB - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds9317790.2
    Total Liabilities1361210.12
    Total Assets1,0669000.18
  • LALPATHLAB - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1891670.13
    Cash from Investing Activity-165-137.650.2
    Cash from Financing Activity12-33.78-1.36
    Net Cash Flow36-4.43-9.13
  • LALPATHLAB - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.190.2
    Return on Equity0.210.24
    Return on Capital Employed0.330.36
  • LALPATHLAB - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.61
    3 Year CAGR Growth in Operating Profit0.7
    3 Year CAGR Growth in EBIDTA0.74
    3 Year CAGR Growth in Net Income0.9
    3 Yr CAGR Growth - Diluted EPS0.25
  • LALPATHLAB - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.43
    5 Year CAGR Growth in Operating Profit1.96
    5 Year CAGR Growth in EBIDTA2.19
    5 Year CAGR Growth in Net Income2.42
    3 Yr CAGR Growth - Diluted EPS-0.79
  • LALPATHLAB - Recent News

    keyboard_arrow_down
    NewsBot
    Today 10:08 AM
    Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs
    Moneycontrol
    NewsBot
    Today 9:36 AM
    Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs
    The Economic Times
    NewsBot
    May 19 4:43 AM
    Sell Dr. Lal PathLabs; target of Rs 895: Prabhudas Lilladher
    Moneycontrol
    NewsBot
    May 9 1:43 AM
    Opportunity is pharma is huge, advise investors to invest: Motilal Oswal
    Moneycontrol
    NewsBot
    May 7 5:33 AM
    Drop airlines! Here are top 10 stocks based on Warren Buffett's investment methodology
    Moneycontrol
    NewsBot
    Apr 30 8:18 AM
    Brokerages initiate buy on 11 stocks after COVID-led fall, expect 10-49% upside
    Moneycontrol
    NewsBot
    Apr 28 1:03 AM
    Hot Stocks | Granules India, Dr Lal Path Lab, Navin Flourine are short-term buys
    Moneycontrol
    NewsBot
    Apr 13 7:43 AM
    Analysts suggest these 15 quality mid-caps for 1-year investment horizon
    Moneycontrol
    NewsBot
    Apr 1 7:53 AM
    Coronavirus pain may linger; 10 stocks you can consider for your portfolio
    Moneycontrol
    NewsBot
    Mar 18 4:58 AM
    Thyrocare Tech, Dr Lal PathLabs rise 9% as govt allow private lab to do coronavirus testing
    Moneycontrol
  • LALPATHLAB - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020